Evidence map›Paper›PMID 40034407›Full record

ArticleBioactive materials2025

Polymer-modified DNA hydrogels for living mitochondria and nanozyme delivery in the treatment of rheumatoid arthritis.

Fuxiao Wang, Yafei Han, Qirong Zhou, Shihao Sheng, Yan Hu, Hao Zhang, Xiao Chen, Chongru He, Hongbo Tan, Long Bai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Bioactives in Food-As-Medicine for Special Medical Purposes.Advances in nutrition (Bethesda, Md.) · 2025
    Review
  17. Review
  18. Article
  19. Stimuli-Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fuxiao WangOrganoid Research Center, Institute of Translational Medicine, Shanghai University, Shanghai 200444, China.
Yafei HanOrganoid Research Center, Institute of Translational Medicine, Shanghai University, Shanghai 200444, China.
Qirong ZhouDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Shihao ShengDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Yan HuDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Hao ZhangDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Xiao ChenDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Chongru HeDepartment of Orthopedics, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Hongbo TanDepartment of Orthopaedics, People's Liberation Army Joint Logistic Support Force 920th Hospital, Kunming City, Yunnan Province, China.
Long BaiOrganoid Research Center, Institute of Translational Medicine, Shanghai University, Shanghai 200444, China.
Jiacan SuOrganoid Research Center, Institute of Translational Medicine, Shanghai University, Shanghai 200444, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to joint deformities and functional impairments. Traditional treatment approaches, such as nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and molecular targeted therapies, often fail to simultaneously achieve efficient inflammation relief and cartilage tissue repair. DNA hydrogels, derived from nucleic acid nanotechnology, have demonstrated potential in RA therapy due to their programmability, high biocompatibility, and tunable degradation properties. However, their application is still hindered by challenges including high synthesis costs, immunogenicity risks, and uncontrolled degradation rates. To address these limitations, this study proposes a dual-action strategy involving a polymer-modified DNA hydrogel co-delivering nanozymes and living mitochondria to overcome the constraints of traditional therapies and comprehensively optimize RA treatment outcomes. The incorporation of functionalized polymers significantly reduces synthesis costs and immunogenicity while fine-tuning the degradation rate of the hydrogel, enabling sustained support during bone and cartilage repair. The hydrogel is loaded with Prussian blue nanozymes to scavenge excessive reactive oxygen species (ROS) within the RA microenvironment, alleviating inflammation, and facilitates intracellular delivery of living mitochondria to inhibit ROS production at its source, promoting tissue repair. By integrating endogenous ROS reduction with exogenous ROS clearance, this strategy markedly enhances therapeutic efficacy, offering a novel approach for precise RA treatment and advancing the clinical translation of biomaterials.

Indexed as

DNA hydrogelMitochondrial deliveryMitochondrial renewalNanozymeRheumatoid arthritis

Identifiers

PMID40034407
PMCPMC11872672

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.